Amgen Drops 10% on a Trial It Didn't Even Run
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
MarketBeat ·